Browse the corpus

REFERENCES Gleave ME, Coupland D, Drachenberg D, et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47:708. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007; 70:315. Hopkins SC, Nissenkorn I, Palmieri GM, et al. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. J Urol 1983; 129:319. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003; 61:993. Bogdanos J, Karamanolakis D, Milathianakis C, et al. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 2003; 23:1757. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011; 117:2077. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813. Sartor AO. Guidelines. American Society of Clinical Oncology 2011. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918. Topic 6948 Version 18.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]